

## CLINICAL RESEARCH

---

# Fractional Flow Reserve–Guided Revascularization

## Practical Implications of a Diagnostic Gray Zone and Measurement Variability on Clinical Decisions

Ricardo Petraco, MD,\* Sayan Sen, MBBS,\* Sukhjinder Nijjer, MBChB,\*  
Mauro Echavarria-Pinto, MD,† Javier Escaned, MD, PhD,†  
Darrel P. Francis, MB, BChIR, MA, MD,\* Justin E. Davies, MBBS, PhD\*

*London, United Kingdom; and Madrid, Spain*

---

**Objectives** This study sought to evaluate the effects of fractional flow reserve (FFR) measurement variability on FFR-guided treatment strategy.

**Background** Current appropriateness guidelines recommend the utilization of FFR to guide coronary revascularization based on a fixed cut-off of 0.8. This rigid approach does not take into account the intrinsic biological variability of a single FFR result and the clinical judgment of experienced interventionists.

**Methods** FFR reproducibility data from the landmark Deferral Versus Performance of PTCA in Patients Without Documented Ischemia (DEFER) trial was analyzed (two repeated FFR measurements in the same lesion, 10 min apart) and the standard deviation of the difference (SDD) between repeated measurements was calculated. The measurement certainty (probability that the FFR-guided revascularization strategy will not change if the test is repeated 10 min later) was subsequently established across the whole range of FFR values, from 0.2 to 1.

**Results** Outside the [0.75 to 0.85] FFR range, measurement certainty of a single FFR result is >95%. However, closer to its cut-off, certainty falls to less than 80% within 0.77 to 0.83, reaching a nadir of 50% around 0.8. In clinical practice, that means that each time a single FFR value falls between 0.75 and 0.85, there is a chance that the FFR-derived revascularization recommendation will change if the measurement is repeated 10 min later, with this chance increasing the closer the FFR result is to 0.8.

**Conclusions** A measurement FFR gray-zone is found between 0.75 and 0.85]. Therefore, clinicians should make revascularization decisions based on broadened clinical judgment when a single FFR result falls within this uncertainty zone, particularly between 0.77 and 0.83, when measurement certainty falls to less than 80%. (J Am Coll Cardiol Intv 2013;6:222–5) © 2013 by the American College of Cardiology Foundation

---

From the \*International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London and Imperial College Healthcare NHS Trust, London, United Kingdom; and the †Cardiovascular Institute, Hospital Clínico San Carlos, Madrid, Spain. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Manuscript received August 23, 2012; revised manuscript received October 1, 2012, accepted October 26, 2012.

Over the last 20 years, the development of fractional flow reserve (FFR) has promoted a major shift in paradigm in assessing coronary stenosis severity in the cardiac catheterization laboratory. Supported by clinical data (1–4), invasive coronary physiology has been shown to improve patient

See page 226

outcomes by selecting patients for percutaneous coronary interventions. At times of increased scientific (5) and public (6) concerns about the appropriateness of coronary revascularization, it is essential that the behavior of FFR is discussed and clearly understood, to focus its application on patients in whom measurements can be interpreted confidently.

The idea of making a strict dichotomous revascularization decision based on a fixed FFR cutoff with nearly absolute diagnostic power was initially received with some skepticism. However, it was subsequently accepted by most cardiologists following demonstration of how physiological stenosis assessment can overcome the limitations of a purely anatomical angiographic approach and improve patient outcomes. This has led to the incorporation of FFR into coronary revascularization guidelines, which currently recommend its clinical use based on a fixed 0.8 cutoff (7–9). But application of a rigid dichotomy may neglect important physiological aspects of FFR, which have implications for its clinical interpretation.

First, it should be remembered that the current evidence on the value of FFR as a clinical decision tool is based on studies that have used 2 different FFR cutoff values. The DEFER (Deferral Versus Performance of PTCA in Patients Without Documented Ischemia) trial (1) demonstrated the safety of a deferral strategy in stenoses with an  $FFR \geq 0.75$ , whereas the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) (3) and FAME II (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation 2) (4) studies used an 0.80 FFR cutoff to investigate its value in guiding angioplasty. This different choice of dichotomous cutoffs has its origin in early validation studies, which demonstrated that an  $FFR < 0.75$  has 100% specificity to identify stenoses with inducible ischemia in noninvasive tests, whereas an  $FFR > 0.80$  has a sensitivity of more than 90% to exclude stenoses that generate myocardial ischemia (10). Because both studies yielded positive results, the most reasonable explanation is that the main determinant of improved patient outcome in the physiology-guided arms was the substitution of angiography by FFR in the decision-making process, not the strict application of either 0.75 or 0.80 FFR cutoffs. Yet, in the post-FAME era, this diagnostic FFR gray zone is not currently incorporated in clinical guidelines (8).

Second, the DEFER-FAME gray zone (0.75 to 0.80) does not take into account the intrinsic variability of FFR measurements, which is important to bear in mind when mandating a strict 0.8 cutoff to guide clinical decisions. For instance, the current approach implies that a difference in FFR as low as 0.01 is enough to mandate a physician to intervene on 1 lesion and forbid a physician from intervening on another. This observation is of particular importance in the context of the current recommendations in clinical practice guidelines, which is the use of FFR in patients with angiographic intermediate coronary lesions of unclear physiological significance (7–9). In contrast to early validation studies of FFR (11–13), which were designed to evaluate the performance of the index across a broad spectrum of coronary stenoses, clinical populations are formed predominantly by physiologically intermediate lesions with unimodally distributed FFR values that straddle the treatment threshold, and a median FFR close to 0.80 (14,15). Therefore, small variations in FFR results could potentially influence clinical decisions in such populations.


To investigate the effects of FFR intrinsic variability on treatment decisions in this clinically relevant zone, we calculated how much the test-retest variability in FFR measurements could affect the certainty of its results, by analyzing the landmark FFR reproducibility data from DEFER (2 repeated FFR measurements, 10 min apart) using a cutoff of 0.80 (1) (Fig. 1A).

We found that, at the extremes of the disease spectrum, the diagnostic agreement between repeated FFR measurements is 100%. Every time cardiologists face a single FFR measurement of  $< 0.75$  or  $> 0.85$ , they can be confident that stenosis classification (and therefore revascularization strategy) is very unlikely to change if FFR is repeated.

Within the region of physiologically intermediate values (0.75 to 0.85), however, the agreement between repeated FFR measurements falls, reaching a nadir of approximately 50% around its 0.80 established clinical cutpoint. In practice, this means that when repeating a measurement that is within 0.01 of the cutoff, the chance of the repeated measure being on the same side of the cutoff is only about a one-half. The further away a single FFR value falls from the 0.80 cutoff, the greater the certainty that the recommended treatment strategy will not be reversed when the test is repeated. Outside the 0.77 to 0.83 range, measurement certainty is approximately 80% and outside the 0.76 to 0.84 range, it is approximately 90%. Measurement certainty only reaches 95% when FFR falls outside the 0.75 to 0.85 range (Fig. 1B). This measurement uncertainty creates a second type of FFR gray zone—a measurement gray zone—which has several important implications, both to the interpretation of available FFR studies and to its application in clinical

#### Abbreviations and Acronyms

FFR = fractional flow  
reserve



**Figure 1. Biological Variability of FFR**

Test-retest reproducibility of 2 repeated measurements of fractional flow reserve (FFR) taken 10 min apart is shown as a scatter plot (**A**, gray dashed envelope demarcates 99% of the data points from 0.5 to 1 and dotted lines show the 0.8 cutoffs). The classification certainty of a single FFR measurement is presented for FFR values from 0.70 to 0.90 (**B**, right vertical axis). Outside the 0.75 to 0.85 range, measurement certainty is higher than 95%. However, closer to its cutpoint, this certainty falls, reaching a nadir of approximately 50% around 0.8. In clinical practice, that means each time a single FFR value falls between 0.75 and 0.85, there is a chance that the dichotomous classification of a stenosis (and therefore the FFR-guided revascularization decision) will change if the test is repeated 10 min later. Within 0.77 to 0.83 this measurement certainty falls to <80%. The FFR diagnostic gray zone (0.75 to 0.85) is also displayed in **B** for comparison. FFR reproducibility data are from the landmark study DEFER (1) and data were obtained and digitized, from Kern et al. (7). Classification certainty (**B**, right vertical axis) was calculated using the standard formula:

$$1 - \left( \frac{1}{2} e^{-\left( \frac{x-0.80}{0.032} \right)^2} \right)$$

With  $x$  representing each FFR value. Constant  $e$  is the base of the natural logarithm and equals 2.718. 0.8 is the currently established cutoff for FFR and 0.032 is the standard deviation of the difference (SDD) between repeated FFR measurements, obtained from the digitized DEFER (Deferral Versus Performance of PTCA in Patients Without Documented Ischemia) reproducibility data. As this analysis was performed using the SDD of the overall population, it could be applied to any FFR cutoff. The chosen FFR cutoff of 0.8 follows current recommendations from clinical guidelines (1) and is in line with the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) (3) and FAME II (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation 2) trials (4).

practice. The causes for this variability are multifactorial and include the variable response of the microcirculation to adenosine (16,17), the systemic vasodilator effects of adenosine influencing aortic blood pressure (18,19), and a possible direct effect of adenosine on myocardial function (20).

Clinicians interpreting the appropriateness criteria for FFR-guided revascularization should be aware of the consequence of natural biological variability of FFR on diagnostic classification of stenoses (Fig. 1). We suggest that when FFR is  $<0.75$  or  $>0.85$ , they can use a strict dichotomous approach based solely on the FFR result, confident that a repeat FFR will recommend the same strategy in  $>95\%$  of occasions. The lower limit (FFR = 0.75) coincides with the initially proposed cutoff from early validation studies and the value above which the safety to defer revascularization has been demonstrated in DEFER. For patients with FFR between 0.75 and 0.85, however, a repeat FFR might allocate the patient to the opposite treatment category, with the chance of change in strategy increasing as FFR approximates to 0.80. Between 0.77 and 0.83, the chance of this happening is as high as 1 in every 5 patients (20%).

In our view, therefore, it would be rational for clinicians to make revascularization decisions based on broadened clinical judgment when FFR values fall in this 0.75 to 0.85 biological variability zone, particularly between 0.77 and 0.83. Within this range, it would be particularly relevant to use all available information (including other perfusion imaging modalities, considering anatomical features and risk-benefit profile) to deliver safe and suitable care for individual patients.

---

**Reprint requests and correspondence:** Dr. Ricardo Petraco International Centre of Circulatory Health, National Heart and Lung Institute, St. Mary's Hospital, Imperial College London, 59-61 North Wharf Road, London W2 1LA, United Kingdom. E-mail: rpetraco@imperial.ac.uk.

---

## REFERENCES

1. Bech GJ, De Bruyne B, Pijls NH, et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. *Circulation* 2001;103:2928-34.
2. Pijls NH, van Schaardenburgh P, Manoharan G, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER study. *J Am Coll Cardiol* 2007;49:2105-11.
3. Tonino PA, De Bruyne B, Pijls NH, et al., for the FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. *N Engl J Med* 2009;360:213-24.
4. De Bruyne B, Pijls NHJ, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. *N Engl J Med* 2012;367:991-1001.
5. Chan PS, Patel MR, Klein LW, et al. Appropriateness of percutaneous coronary intervention. *JAMA* 2011;306:53-61.
6. Winslow R, Carreyrou J. Heart treatment overused: study finds doctors often too quick to try costly procedures to clear arteries. *Wall Street Journal* July 6, 2011.
7. Kern MJ, Lerman A, Bech JW, et al. Physiological assessment of coronary artery disease in the cardiac catheterization laboratory: a scientific statement from the American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology. *Circulation* 2006;114:1321-41.
8. Wijns W, Kolh P, Danchin N, et al., for the Task Force on Myocardial Revascularization of the ESC and EACTS, the EAPCI. Guidelines on myocardial revascularization. *Eur Heart J* 2010;31:2501-55.
9. Patel MR, Dehmer GJ, Hirshfeld JW, et al. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. *J Am Coll Cardiol* 2012;59:857-81.
10. Tonino P, Sels J, Pijls N. Invasive physiological assessment of coronary disease. In: Eeckhout E, Serruys PW, Wijns W, Vahanian A, Van Sambeek M, De Palma R, editors. *Percutaneous Interventional Cardiovascular Medicine: The PCR-EAPCI Textbook*. Payson, AZ: PCR Publishing, 2012:501-25.
11. De Bruyne B, Bartunek J, Sys SU, Pijls NH, Heyndrickx GR, Wijns W. Simultaneous coronary pressure and flow velocity measurements in humans. Feasibility, reproducibility, and hemodynamic dependence of coronary flow velocity reserve, hyperemic flow versus pressure slope index, and fractional flow reserve. *Circulation* 1996;94:1842-9.
12. De Bruyne B, Baudhuin T, Melin JA, et al. Coronary flow reserve calculated from pressure measurements in humans: validation with positron emission tomography. *Circulation* 1994;89:1013-22.
13. Pijls NHJ, De Bruyne B, Peels K, et al. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. *N Engl J Med* 1996;334:1703-8.
14. Petraco R, Escaned J, Sen S, et al. Classification performance of instantaneous wave-free ratio (iFR) and fractional flow reserve in a clinical population of intermediate coronary stenoses: results of the ADVISE registry. *EuroIntervention* 2012 Aug 25 [E-pub ahead of print].
15. Park JJ, Yang HM, Park KW, et al. Diagnostic performance of a novel index, the instantaneous wave-free ratio (iFR), for the detection of functionally significant coronary artery stenosis. (abstr) *EuroIntervention* 2012;8.
16. Cubero JM, de la Llera LSD, García PC, Gil-Ortega MV, Mazuecos JB, Sanchez-Gonzalez A. A comparative study between intravenous and intracoronary administration of high doses adenosine for fractional flow reserve measurements, in the "FAME" era(abstr). *J Am Coll Cardiol* 2012;59:E1465.
17. Meuwissen M, Chamuleau SA, Siebes M, et al. Role of variability in microvascular resistance on fractional flow reserve and coronary blood flow velocity reserve in intermediate coronary lesions. *Circulation* 2001;103:184-7.
18. Cox DA, Vita JA, Treasure CB, Fish RD, Selwyn AP, Ganz P. Reflex increase in blood pressure during the intracoronary administration of adenosine in man. *J Clin Invest* 1989;84:592-6.
19. Sollevi A. Cardiovascular effects of adenosine in man; possible clinical implications. *Prog Neurobiol* 1986;27:319-649.
20. Vinereanu D, Fraser AG, Robinson M, Lee A, Tweddel A. Adenosine provokes diastolic dysfunction in microvascular angina. *Postgrad Med J* 2002;78:40-62.

---

**Key Words:** adenosine ■ coronary physiology ■ coronary revascularization ■ fractional flow reserve.